Global Musculoskeletal Partnering Directory 2014-2020: Deal Trends, Players and Financials for Over 540 Deals –

Global Musculoskeletal Partnering Directory 2014-2020: Deal Trends, Players and Financials for Over 540 Deals –

Global Musculoskeletal Partnering Directory 2014-2020: Deal Trends, Players and Financials for Over 540 Deals –

DUBLIN–(BUSINESS WIRE)–The “Global Musculoskeletal Partnering 2014-2020: Deal Trends, Players and Financials” report has been added to’s offering.

The Global Musculoskeletal Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 540 musculoskeletal deals.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Musculoskeletal deals.

The report presents financial deal terms values for Musculoskeletal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In addition, a comprehensive appendix is provided with each report of all Musculoskeletal partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Musculoskeletal partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Musculoskeletal technologies and products.

Report scope

Global Musculoskeletal Partnering 2014 to 2020 includes:

  • Trends in Musculoskeletal dealmaking in the biopharma industry since 2014
  • Analysis of Musculoskeletal deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Musculoskeletal deal contract documents
  • Comprehensive access to over 540 Musculoskeletal deal records
  • The leading Musculoskeletal deals by value since 2014
  • Most active Musculoskeletal dealmakers since 2014

In Global Musculoskeletal Partnering 2014 to 2020, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The report includes deals for the following indications:

  • Arthritis
  • Ankylosing spondylitis
  • Juvenile arthritis
  • Osteoarthritis
  • Psoriatic arthritis
  • Rheumatoid arthritis
  • Bone fracture
  • Hip
  • Carpel tunnel syndrome
  • Frozen shoulder
  • Gout
  • Knee Meniscus damage
  • Muscular dystrophy
  • Osteoporosis
  • Paget’s disease
  • Spinal muscular atrophy
  • Bone pain
  • Back pain
  • Muscular pain
  • Stiffness
  • Weakness

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Musculoskeletal dealmaking

2.1. Introduction

2.2. Musculoskeletal partnering over the years

2.3. Musculoskeletal partnering by deal type

2.4. Musculoskeletal partnering by industry sector

2.5. Musculoskeletal partnering by stage of development

2.6. Musculoskeletal partnering by technology type

2.7. Musculoskeletal partnering by therapeutic indication

Chapter 3 -Financial deal terms for Musculoskeletal partnering

3.1. Introduction

3.2. Disclosed financials terms for Musculoskeletal partnering

3.3. Musculoskeletal partnering headline values

3.4. Musculoskeletal deal upfront payments

3.5. Musculoskeletal deal milestone payments

3.6. Musculoskeletal royalty rates

Chapter 4 – Leading Musculoskeletal deals and dealmakers

4.1. Introduction

4.2. Most active in Musculoskeletal partnering

4.3. List of most active dealmakers in Musculoskeletal

4.4. Top Musculoskeletal deals by value

Chapter 5 – Musculoskeletal contract document directory

5.1. Introduction

5.2. Musculoskeletal partnering deals where contract document available

Chapter 6 – Musculoskeletal dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Musculoskeletal therapeutic target


  • Appendix 1 – Directory of Musculoskeletal deals by company A-Z since 2014
  • Appendix 2 – Directory of Musculoskeletal deals by deal type since 2014
  • Appendix 3 – Directory of Musculoskeletal deals by stage of development since 2014
  • Appendix 4 – Directory of Musculoskeletal deals by technology type since 2014

For more information about this report visit


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900